vimarsana.com
Home
Live Updates
Europe Approves Paroxysmal Nocturnal Hemoglobinuria Drug : vimarsana.com
Europe Approves Paroxysmal Nocturnal Hemoglobinuria Drug
The factor D inhibitor danicopan has been approved for use in Europe for patients with paroxysmal nocturnal hemoglobinuria with residual hemolytic anemia on standard therapy.
Related Keywords
Japan ,
,
European Union ,
European Medicines Agency ,
European Commission ,
Drug Administration ,
Priority Medicines ,
Medicinal Products ,
Human Use ,
Paroxysmal Nocturnal Hemoglobinuria ,
Nh Paroxysmal Nocturnal Hemoglobinuria ,
Paroxysmal Nocturnal Haemoglobinuria ,
Paroxysmal Nocturnal Hemoglobinuria Pnh ,
Europe ,
European ,
Hemolytic Anemia Haemolytic Anaemia ,
Anemia Anaemia ,
Hemolysis ,
Biologic Therapy ,
Iologics ,
Genomics Genomic Medicine ,
Orphan Drugs ,
Rare Diseases ,
vimarsana.com © 2020. All Rights Reserved.